Drawing for GANBRESO

USPTO serial 86303674

GANBRESO

Reviewed by CopyMark Law Group

Reg. 4820634Status 710
Filing date
Status date
Registration date
Sep 29, 2015
Examiner
MORENO, PAUL A
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.

Status 710: Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active.

Need help with GANBRESO?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Christopher M. Hanes

CHRISTOPHER M. HANES GlaxoSmithKlineFive Moore DriveLegal Global Trademarks, Mailstop: 5.5AResearch Triangle Park, NC 27709-0183

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines(Based on 44(d) Priority Application) Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; VaccinesSECTION 8 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Apr 8, 2022C8..CANCELLED SEC. 8 (6-YR)—
Sep 29, 2020REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
Sep 29, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 14, 2015NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Jul 14, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Jun 24, 2015NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Jun 23, 2015TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 5, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jun 3, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 3, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 3, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
May 27, 2015ALIEASSIGNED TO LIE—
May 21, 2015ERSITEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED—
Mar 26, 2015GNS2NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED—
Mar 26, 2015GNSIINQUIRY TO SUSPENSION E-MAILED—
Mar 26, 2015CNSISUSPENSION INQUIRY WRITTEN—
Sep 19, 2014GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Sep 19, 2014GNSLLETTER OF SUSPENSION E-MAILED—
Sep 19, 2014CNSLSUSPENSION LETTER WRITTEN—
Sep 18, 2014DOCKASSIGNED TO EXAMINER—
Jun 19, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jun 12, 2014NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance